OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
- First Posted Date
- 2013-09-12
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 48
- Registration Number
- NCT01940159
- Locations
- 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States
🇺🇸Collaborative Neuroscience Network, LLC, Long Beach, California, United States
Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder
- First Posted Date
- 2013-09-11
- Last Posted Date
- 2021-10-18
- Target Recruit Count
- 45
- Registration Number
- NCT01939353
Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
- Conditions
- Interventions
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2020-11-20
- Target Recruit Count
- 270
- Registration Number
- NCT01922258
Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2013-07-26
- Last Posted Date
- 2015-07-01
- Target Recruit Count
- 141
- Registration Number
- NCT01909466
- Locations
- 🇺🇸
Collaborative Neuroscience Network, Inc., Garden Grove, California, United States
🇺🇸CNRI-San Diego, San Diego, California, United States
🇺🇸Scientific Clinical Research, Inc., Ft. Lauderdale, Florida, United States
A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot
- Conditions
- Interventions
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2014-01-22
- Target Recruit Count
- 41
- Registration Number
- NCT01870999
- Locations
- 🇺🇸
Otsuka Investigative Site, Austin, Texas, United States
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
- Conditions
- Interventions
- First Posted Date
- 2013-05-24
- Last Posted Date
- 2020-12-31
- Target Recruit Count
- 433
- Registration Number
- NCT01862640
A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)
- Conditions
- Interventions
- First Posted Date
- 2013-05-22
- Last Posted Date
- 2020-11-23
- Target Recruit Count
- 37
- Registration Number
- NCT01859923
- Locations
- 🇵🇭
Lung Center of the Philippines, Quezon City, Metro Manila, Philippines
🇵🇭De La Salle Health Sciences Institute, Dasmariñas, Cavite, Philippines
🇿🇦Brooklyn Chest Hospital, Ysterplaat, Cape Town, South Africa
Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis
- First Posted Date
- 2013-05-17
- Last Posted Date
- 2018-01-30
- Target Recruit Count
- 37
- Registration Number
- NCT01856634
- Locations
- 🇵🇭
De La Salle Health Sciences Institute, Dasmariñas, Cavite, Philippines
🇿🇦Brooklyn Chest Hospital, Ysterplaat, Cape Town, South Africa
PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia
- First Posted Date
- 2013-05-16
- Last Posted Date
- 2016-02-04
- Target Recruit Count
- 12
- Registration Number
- NCT01854944
- Locations
- 🇺🇸
Columbia University, New York, New York, United States
A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial
- Conditions
- Interventions
- First Posted Date
- 2012-11-16
- Last Posted Date
- 2018-06-08
- Target Recruit Count
- 2182
- Registration Number
- NCT01727726